Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Dyno Therapeutics, a US-based gene therapy platform developer spun out of Harvard Medical School, emerged from stealth yesterday with $9m in seed financing co-led by Polaris Partners and CRV to commercialise treatments for several disease populations. Dyno Therapeutics has built an artificial intelligence-driven drug design platform for identifying viral vectors for gene therapies to gain…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.